Navigation Links
Exenatide Clinical Data Analysis Shows No Increased Risk of Cardiovascular Events
Date:3/26/2009

ekly," said Orville G. Kolterman, M.D., senior vice president of research and development at Amylin. "If approved, this therapy has the potential to become the first weekly therapy to treat type 2 diabetes with glucose control and weight loss. This could offer a unique value proposition for patients, payers and physicians."

Initiation Of New DURATION-5 Clinical Study

The companies have initiated DURATION-5, a new phase 3b study in which patients with type 2 diabetes will use exenatide once weekly commercial-scale drug product in its final commercial configuration. This randomized, 26-week, open-label study in approximately 240 patients has broad utility and is designed to show superiority of exenatide once weekly compared to BYETTA, support regulatory submissions outside the United States and provide additional controlled clinical data on the commercially manufactured product.

"In the near-term, we are working to bring this important therapy to market as quickly as possible," said David Vondle, Lilly's global brand development leader for exenatide. "In the long-term, we are executing on a clinical trial program aimed to show superiority of exenatide once weekly over other diabetes medications."

About Diabetes

Diabetes affects more than 23 million people in the United States and an estimated 246 million adults worldwide.(i,ii) Approximately 90-95 percent of those affected have type 2 diabetes. Diabetes is the fifth leading cause of death by disease in the United States and costs approximately $132 billion per year in direct and indirect medical expenses.(iii)

According to the Centers for Disease Control and Prevention's National Health and Nutrition Examination Survey, approximately 60 percent of people with diabetes do not achieve their target blood sugar levels with their current treatment regimen.(iv) In addition, 85 percent of type 2 diabetes patients are overw
'/>"/>

SOURCE Amylin Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. New Data From Head-to-Head Phase 3 Trial Demonstrate That Liraglutide is More Effective Than Exenatide in Treatment of Type 2 Diabetes
2. Lilly and Amylin Enter Into Supply Agreement for Exenatide Once Weekly
3. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
4. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
5. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
6. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
7. PNH Patients Treated with Soliris(TM) Experienced Dramatic Reduction in Blood Clots During Clinical Trials
8. Clinical Data Acquires Epidauros Biotechnologie AG, Significantly Enhancing Proprietary Genetic Biomarker Portfolio
9. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
10. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
11. Lorus Advances Clinical Development of GTI-2040 Combined with Ara-C in Acute Myeloid Leukemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... A study has been launched to test ... track could help to tackle the problem of obesity.  This ... GP surgery based in Stowmarket) and academics at University Campus ... Telemetry technology, which is inspired by equipment used to collect ...
(Date:1/15/2014)... Two champions of science, technology, engineering, ... an annual competition for middle and high school students ... STEM study. The competition presents students with real-world problems ... Aptitude, Mathematics, and Sciences is a program administered ...
(Date:1/15/2014)... 15, 2014 DTS Language Services, Inc ... Web Portal for Life Science organizations who need document translations. ... subject matter of their documents in advance with a selection ... time-to-delivery of translations, often a critical factor in clinical and ...
(Date:1/15/2014)... Freeslate, Inc ., the leading ... Lupin Limited, one of India’s top five pharmaceutical companies, ... System for high throughput solid form screening. ... a wide range of quality, affordable generic and branded ...
Breaking Biology Technology:Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 2Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 3Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 4Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 2Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 3Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 4Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 5DTS Improves Efficiency for Life Science Document Translations 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3
... are exposed to sunlight? And how is the skin affected ... subject of research at the University of Gothenburg and Chalmers ... dermatologist conference in Gothenburg. A growing hole in the ... an increase in the number of cases of skin cancer ...
... 12 Beta-Pro LLC, announced today that it ... from pharmaceutical drug discovery and research institutes in ... sciences company now manages extensive laboratory facilities in ... Virginia.   "Beta-Pro has already established ...
... 12 WaferGen Biosystems, Inc. (OTC Bulletin Board: ... analysis systems, today announced that Gary P. Schroth, Ph.D., ... sequencing for gene expression at Illumina, Inc., has joined ... Applications, a new position created to build on the ...
Cached Biology Technology:So that's why we're allergic to sun creams 2Beta-Pro Expands Operations to Meet Demands for Human Cells in Hepatocyte Drug Discovery Market 2WaferGen Names Gary P. Schroth, Ph.D., as New SVP, Genomics Research and Applications 2WaferGen Names Gary P. Schroth, Ph.D., as New SVP, Genomics Research and Applications 3WaferGen Names Gary P. Schroth, Ph.D., as New SVP, Genomics Research and Applications 4WaferGen Names Gary P. Schroth, Ph.D., as New SVP, Genomics Research and Applications 5
(Date:4/17/2014)... trials to treat tuberculosis could be the basis for ... bacteria, fungal infections and parasites, yet evade resistance, according ... collaborators. , Led by U. of I. chemistry professor ... drug SQ109 attacks the tuberculosis bacterium, how the drug ... to malaria and how targeting multiple pathways reduces ...
(Date:4/17/2014)... West Orange, NJ. April 16, 2014. Kessler Foundation ... for $1.8 million from the Department of Defense ... PhD, is principal investigator for the randomized, double-blinded, ... to improve bone and muscle strength after spinal ... Human Performance & Engineering Research at Kessler Foundation. ...
(Date:4/17/2014)... Occurring in about one per eight hundred births, Down ... frequent genetic cause of intellectual disability. It results from ... a third copy of chromosome 21 (1% of the ... his team in the Department of Genetic Medicine and ... Medicine, published in Nature , shed light on ...
Breaking Biology News(10 mins):Multitarget TB drug could treat other diseases, evade resistance 2Kessler Foundation awarded Department of Defense grant for spinal cord injury research 2Trisomy 21: How an extra little chromosome throws the entire genome off balance 2Trisomy 21: How an extra little chromosome throws the entire genome off balance 3
... Université Laval biologist Connie Lovejoy has discovered new ... findings are reported in the January 12 edition ... discovered a new group of microscopic organisms, which ... extremely small size, measured in millionths of a ...
... to protect against human papillomavirus, has moved from scientific ... to make progress. While HPV vaccine efforts had the ... researchers are developing vaccines for cancers that are not ... system into attacking cancerous cells. Today at the ...
... from West Africa were cracking nuts with stone tools ... The result suggests chimpanzees developed this behaviour on their ... trait inherited from our common ancestor. Julio Mercader, Christophe ... site in Cote d'Ivoire, the only known prehistoric chimpanzee ...
Cached Biology News:Cancer vaccines -- Taking a jab at cancer by stimulating the immune system 2Cancer vaccines -- Taking a jab at cancer by stimulating the immune system 3Cancer vaccines -- Taking a jab at cancer by stimulating the immune system 4Cancer vaccines -- Taking a jab at cancer by stimulating the immune system 5The chimpanzee stone age 2
...
Immunogen: Synthetic peptide: R(89) L A F T V D D N P T K P T T R Q R Y(107) Storage: -20 C, Avoid Freeze/Thaw Cycles...
...
Liquid. Phycoerythrin conjugate is in PBS, pH 7.4 containing 1% BSA and 0.1% sodium azide....
Biology Products: